Progress and prospects in pharmacogenetics of antidepressant drugs

Expert Opinion on Drug Metabolism and Toxicology

Volumn 12, Issue 10, 2016, Pages 1157-1168

  Fabbri, Chiara ^a   Crisafulli, Concetta ^b   Calabrò, Marco ^b   Spina, Edoardo ^b   Serretti, Alessandro ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

Author keywords

antidepressant; gene; GWAS; Major depression; pharmacogenomics; polymorphism; tailored treatment

Indexed keywords

ANTIDEPRESSANT AGENT;

DRUG METABOLISM; DRUG TRANSPORT; GENE; GENE EXPRESSION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOME-WIDE ASSOCIATION STUDY; HUMAN; MAJOR DEPRESSION; NONHUMAN; PHARMACOGENETICS; PROGNOSIS; REVIEW; RISK; ANIMAL; COST OF ILLNESS; DEPRESSIVE DISORDER, MAJOR; GENE EXPRESSION REGULATION; GENETICS;

ANIMALS; ANTIDEPRESSIVE AGENTS; COST OF ILLNESS; DEPRESSIVE DISORDER, MAJOR; GENE EXPRESSION REGULATION; GENOME-WIDE ASSOCIATION STUDY; HUMANS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PROGNOSIS;

EID: 84987811430     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1080/17425255.2016.1202237     Document Type: Review

References (116)

1. K.Demyttenaere, R.Bruffaerts, J.Posada-Villa, et al. Prevalence, severity, and unmet need for treatment of mental disorders in the world health organization world mental health surveys. JAMA. 2004;291:2581–2590.
2. Global Burden of Disease Study Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990–2013:a systematic analysis for the global burden of disease study 2013. Lancet. 2015;386:743–800.
3. S.Leucht, S.Hierl, W.Kissling, et al. Putting the efficacy of psychiatric and general medicine medication into perspective:review of meta-analyses. Br J Psychiatry. 2012;200:97–106.
4. M.H.Trivedi, A.J.Rush, S.R.Wisniewski, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D:implications for clinical practice. Am J Psychiatry. 2006;163:28–40.
5. D.Souery, A.Serretti, R.Calati, et al. Switching antidepressant class does not improve response or remission in treatment-resistant depression. J Clin Psychopharmacol. 2011;31:512–516.
6. R.L.O’Reilly, L.Bogue, S.M.Singh Pharmacogenetic response to antidepressants in a multicase family with affective disorder. Biol Psychiatry. 1994;36:467–471.
7. C.M.Pare, L.Rees, M.J.Sainsbury. Differentiation of two genetically specific types of depression by the response to anti-depressants. Lancet. 1962;2:1340–1343.
8. L.Franchini, A.Serretti, M.Gasperini, et al. Familial concordance of fluvoxamine response as a tool for differentiating mood disorder pedigrees. J Psychiatr Res. 1998;32:255–259.
9. C.Fabbri, G.Di Girolamo, A.Serretti. Pharmacogenetics of antidepressant drugs:an update after almost 20 years of research. Am J Med Genet B Neuropsychiatr Genet. 2013;162B:487–520.
10. J.R.Homberg, K.-P.Lesch. Looking on the bright side of serotonin transporter gene variation. Biol Psychiatry. 2011;69:513–519.
11. S.Porcelli, C.Fabbri, A.Serretti. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy. Eur Neuropsychopharmacol. 2012;22:239–258.
12. Y.Ma, B.Li, C.Wang, et al. Allelic variation in 5-HTTLPR and the effects of citalopram on the emotional neural network. Br J Psychiatry. 2015;206:385–392.
13. P.R.Shiroma, M.S.Drews, J.R.Geske, et al. SLC6A4 polymorphisms and age of onset in late-life depression on treatment outcomes with citalopram:a sequenced treatment alternatives to relieve depression (STAR*D) report. Am J Geriatr Psychiatry. 2014;22:1140–1148.
14. J.Pacheco, C.G.Beevers, C.Benavides, et al. Frontal-limbic white matter pathway associations with the serotonin transporter gene promoter region (5-HTTLPR) polymorphism. J Neurosci. 2009;29:6229–6233.
15. B.Vai, S.Poletti, D.Radaelli, et al. Successful antidepressant chronotherapeutics enhance fronto-limbic neural responses and connectivity in bipolar depression. Psychiatry Res. 2015;233:243–253.
16. G.Qesseveur, A.C.Petit, H.T.Nguyen, et al. Genetic dysfunction of serotonin 2A receptor hampers response to antidepressant drugs:a translational approach. Neuropharmacology. 2016;105:142–153.
17. J.-Y.Lin, M.-Y.Jiang, Z.-M.Kan, et al. Influence of 5-HTR2A genetic polymorphisms on the efficacy of antidepressants in the treatment of major depressive disorder:a meta-analysis. J Affect Disord. 2014;168:430–438.
18. C.Fabbri, A.Marsano, D.Albani, et al. PPP3CC gene:a putative modulator of antidepressant response through the B-cell receptor signaling pathway. Pharmacogenomics J. 2014;14:463–472.
19. G.Laje, D.M.Cannon, A.S.Allen, et al. Genetic variation in HTR2A influences serotonin transporter binding potential as measured using PET and [11C]DASB. Int J Neuropsychopharmacol. 2010;13:715–724.
20. H.Vermeer, B.I.Hendriks-Stegeman, B.van der Burg, et al. Glucocorticoid-induced increase in lymphocytic FKBP51 messenger ribonucleic acid expression:a potential marker for glucocorticoid sensitivity, potency, and bioavailability. J Clin Endocrinol Metab. 2003;88:277–284.
21. G.Guidotti, F.Calabrese, C.Anacker, et al. Glucocorticoid receptor and FKBP5 expression is altered following exposure to chronic stress:modulation by antidepressant treatment. Neuropsychopharmacology. 2013;38:616–627.
22. A.Cattaneo, M.Gennarelli, R.Uher, et al. Candidate genes expression profile associated with antidepressants response in the GENDEP study:differentiating between baseline ‘predictors’ and longitudinal ‘targets’. Neuropsychopharmacology. 2013;38:377–385.
23. E.B.Binder, D.Salyakina, P.Lichtner, et al. Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat Genet. 2004;36:1319–1325.
24. T.Niitsu, C.Fabbri, F.Bentini, et al. Pharmacogenetics in major depression:a comprehensive meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry. 2013;45:183–194.•• Recent and comprehensive meta-analysis of the main polymorphisms implicated in antidepressant response.
25. V.Ruiz-Velasco, S.R.Ikeda. A splice variant of the G protein beta 3-subunit implicated in disease states does not modulate ion channels. Physiol Genom. 2003;13:85–95.
26. Q.Hu, S.Y.Zhang, F.Liu, et al. Influence of GNB3 C825T polymorphism on the efficacy of antidepressants in the treatment of major depressive disorder:a meta-analysis. J Affect Disord. 2014;172C:103–109.
27. C.E.Glatt, F.S.Lee. Common polymorphisms in the age of research domain criteria (RDoC):integration and translation. Biol Psychiatry. 2016;79:25–31.
28. A.Govindarajan, B.S.Rao, D.Nair, et al. Transgenic brain-derived neurotrophic factor expression causes both anxiogenic and antidepressant effects. Proc Natl Acad Sci U S A. 2006;103:13208–13213.
29. GENDEP Investigators, MARS Investigators, STAR*D Investigators. Common genetic variation and antidepressant efficacy in major depressive disorder:a meta-analysis of three genome-wide pharmacogenetic studies. Am J Psychiatry. 2013;170:207–217.•• Largest available meta-analysis of genome-wide association studies investigating antidepressant response.
30. Ricopili, a tool for visualizing regions of interest in selected GWAS data sets. Institute B. 2011. Available from: http://www.broadinstitute.org/mpg/ricopili/.• Tool for visualising genetic findings from the largest meta-analysis of genome-wide association studies investigating antidepressant response.
31. C.Hiemke, S.Härtter. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther. 2000;85:11–28.
32. A.Hemeryck, F.M.Belpaire. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions:an update. Curr Drug Metab. 2002;3:13–37.
33. E.Spina, M.G.Scordo, C.D’Arrigo. Metabolic drug interactions with new psychotropic agents. Fundam Clin Pharmacol. 2003;17:517–538.
34. S.V.Bhagwat, S.Bhamre, M.R.Boyd, et al. Cerebral metabolism of imipramine and a purified flavin-containing monooxygenase from human brain. Neuropsychopharmacology. 1996;15:133–142.
35. V.G.Manolopoulos. Pharmacogenomics and adverse drug reactions in diagnostic and clinical practice. Clin Chem Lab Med. 2007;45:801–814.
36. E.Spina, J.de Leon. Clinical applications of CYP genotyping in psychiatry. J Neural Transm (Vienna). 2015;122:5–28.• Recent review focused on clinical applications of CYP genotyping.
37. S.Porcelli, C.Fabbri, E.Spina, et al. Genetic polymorphisms of cytochrome P450 enzymes and antidepressant metabolism. Expert Opin Drug Metab Toxicol. 2011;7:1101–1115.
38. D.R.Nelson, D.C.Zeldin, S.M.Hoffman, et al. Comparison of cytochrome P450 (CYP) genes from the mouse and human genomes, including nomenclature recommendations for genes, pseudogenes and alternative-splice variants. Pharmacogenetics. 2004;14:1–18.
39. U.A.Meyer. Pharmacogenetics and adverse drug reactions. Lancet. 2000;356:1667–1671.
40. J.J.Swen, M.Nijenhuis, A.De Boer, et al. Pharmacogenetics:from bench to byte – an update of guidelines. Clin Pharmacol Ther. 2011;89:662–673.
41. M.-H.Tsai, K.-M.Lin, M.-C.Hsiao, et al. Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response. Pharmacogenomics. 2010;11:537–546.
42. E.J.Peters, S.L.Slager, J.B.Kraft, et al. Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample. PLoS One. 2008;3:e1872.
43. C.Kawanishi, S.Lundgren, H.Agren, et al. Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders:ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study. Eur J Clin Pharmacol. 2004;59:803–807.
44. T.Rau, G.Wohlleben, H.Wuttke, et al. CYP2D6 genotype:impact on adverse effects and nonresponse during treatment with antidepressants-a pilot study. Clin Pharmacol Ther. 2004;75:386–393.
45. A.L.Zackrisson, B.Lindblom, J.Ahlner. High frequency of occurrence of CYP2D6 gene duplication/multiduplication indicating ultrarapid metabolism among suicide cases. Clin Pharmacol Ther. 2010;88:354–359.
46. D.J.Müller, I.Kekin, A.C.Kao, et al. Towards the implementation of CYP2D6 and CYP2C19 genotypes in clinical practice:update and report from a pharmacogenetic service clinic. Int Rev Psychiatry. 2013;25:554–571.
47. E.Spina, F.Pisani, J.de Leon. Clinically significant pharmacokinetic drug interactions of antiepileptic drugs with new antidepressants and new antipsychotics. Pharmacol Res. 2016;106:72–86.
48. K.Linnet. Glucuronidation of olanzapine by cDNA-expressed human UDP-glucuronosyltransferases and human liver microsomes. Hum Psychopharmacol. 2002;17:233–238.
49. U.Breyer-Pfaff, U.Mey, M.D.Green, et al. Comparative N-glucuronidation kinetics of ketotifen and amitriptyline by expressed human UDP-glucuronosyltransferases and liver microsomes. Drug Metab Dispos. 2000;28:869–872.
50. D.Zhou, J.Guo, A.J.Linnenbach, et al. Role of human UGT2B10 in N-glucuronidation of tricyclic antidepressants, amitriptyline, imipramine, clomipramine, and trimipramine. Drug Metab Dispos. 2010;38:863–870.
51. M.Iwai, Y.Maruo, M.Ito, et al. Six novel UDP-glucuronosyltransferase (UGT1A3) polymorphisms with varying activity. J Hum Genet. 2004;49:123–128.
52. A.Mori, Y.Maruo, M.Iwai, et al. UDP-glucuronosyltransferase 1A4 polymorphisms in a Japanese population and kinetics of clozapine glucuronidation. Drug Metab Dispos. 2005;33:672–675.
53. S.Fowler, H.Kletzl, M.Finel, et al. A UGT2B10 splicing polymorphism common in african populations may greatly increase drug exposure. J Pharmacol Exp Ther. 2015;352:358–367.
54. C.Fabbri, A.Serretti. Pharmacogenetics of major depressive disorder:top genes and pathways toward clinical applications. Curr Psychiatry Rep. 2015;17:50.
55. M.Kato, T.Fukuda, A.Serretti, et al. ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32:398–404.
56. G.Nikisch, C.B.Eap, P.Baumann. Citalopram enantiomers in plasma and cerebrospinal fluid of ABCB1 genotyped depressive patients and clinical response:a pilot study. Pharmacol Res. 2008;58:344–347.
57. M.Uhr, A.Tontsch, C.Namendorf, et al. Polymorphisms in the drug transporter gene ABCB1 predict antidepressant treatment response in depression. Neuron. 2008;57:203–209.
58. J.E.Sarginson, L.C.Lazzeroni, H.S.Ryan, et al. ABCB1 (MDR1) polymorphisms and antidepressant response in geriatric depression. Pharmacogenet Genom. 2010;20:467–475.
59. B.Breitenstein, T.M.Brückl, M.Ising, et al. ABCB1 gene variants and antidepressant treatment outcome:a meta-analysis. Am J Med Genet B Neuropsychiatr Genet. 2015;168B:274–283.
60. A.F.Schatzberg, C.DeBattista, L.C.Lazzeroni, et al. ABCB1 genetic effects on antidepressant outcomes:a report from the iSPOT-D trial. Am J Psychiatry. 2015;172:751–759.
61. Schizophrenia Working Group of the Psychiatric Genomics C. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014;511:421–427.
62. R.Uher, N.Perroud, M.Y.Ng, et al. Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. Am J Psychiatry. 2010;167:555–564.
63. H.A.Garriock, J.B.Kraft, S.I.Shyn, et al. A genomewide association study of citalopram response in major depressive disorder. Biol Psychiatry. 2010;67:133–138.
64. M.Ising, S.Lucae, E.B.Binder, et al. A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression. Arch Gen Psychiatry. 2009;66:966–975.
65. W.Myung, J.Kim, S.-W.Lim, et al. A genome-wide association study of antidepressant response in Koreans. Transl Psychiatry. 2015;5:e633.
66. J.M.Biernacka, K.Sangkuhl, G.Jenkins, et al. The international SSRI pharmacogenomics consortium (ISPC):a genome-wide association study of antidepressant treatment response. Transl Psychiatry. 2015;5:e553.
67. D.Sasayama, A.Hiraishi, M.Tatsumi, et al. Possible association of CUX1 gene polymorphisms with antidepressant response in major depressive disorder. Pharmacogenomics J. 2013;13:354–358.
68. M.-L.Wong, C.Dong, D.L.Flores, et al. Clinical outcomes and genome-wide association for a brain methylation site in an antidepressant pharmacogenetics study in Mexican Americans. Am J Psychiatry. 2014;171:1297–1309.
69. A.Tammiste, T.Jiang, K.Fischer, et al. Whole-exome sequencing identifies a polymorphism in the BMP5 gene associated with SSRI treatment response in major depression. J Psychopharmacol. 2013;27:915–920.
70. C.O’Dushlaine, S.Ripke, D.M.Ruderfer, et al. Rare copy number variation in treatment-resistant major depressive disorder. Biol Psychiatry. 2014;76:536–541.
71. K.E.Tansey, J.J.Rucker, D.H.Kavanagh, et al. Copy number variants and therapeutic response to antidepressant medication in major depressive disorder. Pharmacogenomics J. 2014;14:395–399.
72. N.Oksenberg, N.Ahituv. The role of AUTS2 in neurodevelopment and human evolution. Trends Genet. 2013;29:600–608.
73. M.L.Hamshere, E.K.Green, I.R.Jones, et al. Genetic utility of broadly defined bipolar schizoaffective disorder as a diagnostic concept. Br J Psychiatry. 2009;195:23–29.
74. E.Hattori, T.Toyota, Y.Ishitsuka, et al. Preliminary genome-wide association study of bipolar disorder in the Japanese population. Am J Med Genet B Neuropsychiatr Genet. 2009;150B:1110–1117.
75. R.Uher, S.Ripke, B.Müller-Myhsok, et al. Association of a brain methylation site with clinical outcomes in depression does not replicate across populations. Am J Psychiatry. 2015;172:395–397.
76. A.M.Hunter, A.F.Leuchter, R.A.Power, et al. A genome-wide association study of a sustained pattern of antidepressant response. J Psychiatr Res. 2013;47:1157–1165.
77. C.Fabbri, C.Crisafulli, D.Gurwitz, et al. Neuronal cell adhesion genes and antidepressant response in three independent samples. Pharmacogenomics J. 2015;15:538–548.
78. S.Moosmang, N.Haider, N.Klugbauer, et al. Role of hippocampal Cav1.2 Ca2+ channels in NMDA receptor-independent synaptic plasticity and spatial memory. J Neurosci. 2005;25:9883–9892.
79. C.Pittenger, R.S.Duman. Stress, depression, and neuroplasticity:a convergence of mechanisms. Neuropsychopharmacology. 2008;33:88–109.
80. A.Tanti, C.Belzung. Neurogenesis along the septo-temporal axis of the hippocampus:are depression and the action of antidepressants region-specific? Neuroscience. 2013;252:234–252.
81. L.M.Bronicki, B.J.Jasmin. Emerging complexity of the HuD/ELAVl4 gene; implications for neuronal development, function, and dysfunction. Rna. 2013;19:1019–1037.
82. R.N.Pechnick, S.Zonis, K.Wawrowsky, et al. Antidepressants stimulate hippocampal neurogenesis by inhibiting p21 expression in the subgranular zone of the hipppocampus. PLoS One. 2011;6:e27290.
83. J.R.Epp, C.L.Beasley, L.A.Galea. Increased hippocampal neurogenesis and p21 expression in depression:dependent on antidepressants, sex, age, and antipsychotic exposure. Neuropsychopharmacology. 2013;38:2297–2306.
84. A.Pedram, M.Razandi, R.J.Deschenes, et al. DHHC-7 and −21 are palmitoylacyltransferases for sex steroid receptors. Mol Biol Cell. 2012;23:188–199.
85. Y.Ooishi, S.Kawato, Y.Hojo, et al. Modulation of synaptic plasticity in the hippocampus by hippocampus-derived estrogen and androgen. J Steroid Biochem Mol Biol. 2012;131:37–51.
86. G.Parker, H.Brotchie. Gender differences in depression. Int Rev Psychiatry. 2010;22:429–436.
87. M.Sairanen, O.F.O’Leary, J.E.Knuuttila, et al. Chronic antidepressant treatment selectively increases expression of plasticity-related proteins in the hippocampus and medial prefrontal cortex of the rat. Neuroscience. 2007;144:368–374.
88. S.-H.Park, S.-H.Choi, J.Lee, et al. Effects of repeated citalopram treatments on chronic mild stress-induced growth associated protein-43 mRNA expression in rat hippocampus. Korean J Physiol Pharmacol. 2008;12:117–123.
89. R.Strawbridge, D.Arnone, A.Danese, et al. Inflammation and clinical response to treatment in depression:a meta-analysis. Eur Neuropsychopharmacol. 2015;25:1532–1543.•• Recent meta-analysis of inflammatory biomarkers associated with antidepressant response and treatment resistance.
90. H.Eyre, B.T.Baune. Neuroplastic changes in depression:a role for the immune system. Psychoneuroendocrinology. 2012;37:1397–1416.
91. S.P.Hagenaars, S.E.Harris, G.Davies, et al. Shared genetic aetiology between cognitive functions and physical and mental health in UK Biobank (N=112 151) and 24 GWAS consortia. Mol Psychiatry. 2016. [Epub ahead of print].
92. K.E.Tansey, M.Guipponi, X.Hu, et al. Contribution of common genetic variants to antidepressant response. Biol Psychiatry. 2013;73:679–682.• This study provided the first estimation of the contribution of common variants to the variance in antidepressant response.
93. D.S.Tylee, D.M.Kawaguchi, S.J.Glatt. On the outside, looking in:a review and evaluation of the comparability of blood and brain “-omes”. Am J Med Genet B Neuropsychiatr Genet. 2013;162B:595–603.
94. A.Cattaneo, L.Bocchio-Chiavetto, R.Zanardini, et al. Reduced peripheral brain-derived neurotrophic factor mRNA levels are normalized by antidepressant treatment. Int J Neuropsychopharmacol. 2010;13:103–108.
95. J.P.Lopez, F.Mamdani, B.Labonte, et al. Epigenetic regulation of BDNF expression according to antidepressant response. Mol Psychiatry. 2013;18:398–399.
96. P.S.Rojas, R.Fritsch, R.A.Rojas, et al. Serum brain-derived neurotrophic factor and glucocorticoid receptor levels in lymphocytes as markers of antidepressant response in major depressive patients:a pilot study. Psychiatry Res. 2011;189:239–245.
97. F.Mamdani, M.T.Berlim, M.-M.Beaulieu, et al. Gene expression biomarkers of response to citalopram treatment in major depressive disorder. Transl Psychiatry. 2011;1:e13.
98. J.M.Hennings, M.Uhr, T.Klengel, et al. RNA expression profiling in depressed patients suggests retinoid-related orphan receptor alpha as a biomarker for antidepressant response. Transl Psychiatry. 2015;5:e538.
99. R.Belzeaux, A.Bergon, V.Jeanjean, et al. Responder and nonresponder patients exhibit different peripheral transcriptional signatures during major depressive episode. Transl Psychiatry. 2012;2:e185.
100. J.-P.Guilloux, S.Bassi, Y.Ding, et al. Testing the predictive value of peripheral gene expression for nonremission following citalopram treatment for major depression. Neuropsychopharmacology. 2015;40:701–710.
101. J.Winner, J.D.Allen, C.A.Altar, et al. Psychiatric pharmacogenomics predicts health resource utilization of outpatients with anxiety and depression. Transl Psychiatry. 2013;3:e242.
102. D.K.Hall-Flavin, J.G.Winner, J.D.Allen, et al. Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting. Pharmacogenet Genom. 2013;23:535–548.
103. J.G.Winner, J.M.Carhart, C.A.Altar, et al. Combinatorial pharmacogenomic guidance for psychiatric medications reduces overall pharmacy costs in a 1 year prospective evaluation. Curr Med Res Opin. 2015;31:1633–1643.
104. B.D.Jamerson, M.E.Payne, M.E.Garrett, et al. Folate metabolism genes, dietary folate and response to antidepressant medications in late-life depression. Int J Geriatr Psychiatry. 2013;28:925–932.
105. L.I.Serova, M.Laukova, L.G.Alaluf, et al. Intranasal infusion of melanocortin receptor four (MC4R) antagonist to rats ameliorates development of depression and anxiety related symptoms induced by single prolonged stress. Behav Brain Res. 2013;250:139–147.
106. H.A.Garriock, M.Tanowitz, J.B.Kraft, et al. Association of mu-opioid receptor variants and response to citalopram treatment in major depressive disorder. Am J Psychiatry. 2010;167:565–573.
107. F.X.Brennan, K.R.Gardner, J.Lombard, et al. A naturalistic study of the effectiveness of pharmacogenetic testing to guide treatment in psychiatric patients with mood and anxiety disorders. Prim Care Companion CNS Disord. 2015;17:e1–e7.
108. J.Fagerness, E.Fonseca, G.P.Hess, et al. Pharmacogenetic-guided psychiatric intervention associated with increased adherence and cost savings. Am J Manag Care. 2014;20:e146–e156.
109. A.B.Singh. Improved antidepressant remission in major depression via a pharmacokinetic pathway polygene pharmacogenetic report. Clin Psychopharmacol Neurosci. 2015;13:150–156.
110. B.Breitenstein, S.Scheuer, H.Pfister, et al. The clinical application of ABCB1 genotyping in antidepressant treatment:a pilot study. CNS Spectr. 2014;19:165–175.
111. B.Breitenstein, S.Scheuer, T.M.Brückl, et al. Association of ABCB1 gene variants, plasma antidepressant concentration, and treatment response:results from a randomized clinical study. J Psychiatr Res. 2016;73:86–95.
112. T.J.Stamm, C.Rampp, K.Wiethoff, et al. The FKBP5 polymorphism rs1360780 influences the effect of an algorithm-based antidepressant treatment and is associated with remission in patients with major depression. J Psychopharmacol. 2016;30:40–47.
113. M.T.Lee, S.Mahasirimongkol, Y.Zhang, et al. Clinical application of pharmacogenomics:the example of HLA-based drug-induced toxicity. Public Health Genom. 2014;17:248–255.
114. G.Laje. Pharmacogenetics of mood disorders:what clinicians need to know. CNS Spectr. 2013;18:272–284.
115. P.Olgiati, E.Bajo, M.Bigelli, et al. Should pharmacogenetics be incorporated in major depression treatment? Economic evaluation in high- and middle-income European countries. Prog Neuropsychopharmacol Biol Psychiatry. 2012;36:147–154.
116. S.H.Katsanis, M.A.Minear, A.Vorderstrasse, et al. Perspectives on genetic and genomic technologies in an academic medical center:the duke experience. J Pers Med. 2015;5:67–82.